Patients Stopping Weight-Loss Medications Gain Back Weight at a Quadrupled Rate Than Those on Conventional Diets

A recent study indicates that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end conventional lifestyle programs.

Published data in a prominent health publication points out that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month after stopping.

"Individuals purchasing these drugs should be informed of the danger of quick rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.

Such speed of regain suggests a reversion to original weight within about a year and a half.

Comparing Therapies

The analysis, which examined dozens of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods.

The team note that people who lose weight through lifestyle changes alone generally have a less rapid weight regain—around 100 grams monthly—post-intervention.

Explaining the Rapid Rebound

Experts believe the way of the drugs accounts for the accelerated weight return.

The injections copy a natural hormone called GLP-1, which controls hunger.

"Long-term administration of GLP-1 concentrations several times higher than normal may cause the system to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this GLP-1 'fix' results in hunger is unsuppressed, making binge eating a significant risk."

A Lifelong Condition?

Health authorities suggest the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.

Professionals say that, due to the likelihood of weight regain, the therapy is often long-term.

This perspective is supported by drug manufacturers, who note that the findings "emphasize the persistent character of obesity," similar to managing conditions like hypertension.

User Testimonies

People who have come off the medication report a sudden resurgence of hunger.

"I experienced something activating and you become ravenous," described one woman.

This difficulty is compounded if users have not established lasting dietary or behavioural modifications during therapy.

Significant Use

Recent estimates indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire being substantial.

• Use is more common among females than men.
• The middle-aged demographic shows the greatest level of interest.
• Many access the drugs through private prescriptions rather than public health services.

Ultimately, experts emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on combined behavioural support.